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Abstract Chronic post-surgical pain (CPSP) is a serious
complication of major surgery that can impair a patient’s
quality of life. The development of CPSP is a complex
process which involves biologic, psychosocial, and envi-
ronmental mechanisms that have yet to be fully understood.
Currently perioperative pharmacologic interventions aim to
suppress and prevent sensitization with the aim of reducing
pain and analgesic requirement in acute as well as long-term
pain . Despite the detrimental effects of CPSP on patients, the
body of literature focused on treatment strategies to reduce
CPSP remains limited and continues to be understudied. This
article reviews the main pharmacologic candidates for the
treatment of CPSP, discusses the future of preventive anal-
gesia, and considers novel strategies to help treat acute post-
operative pain and lessen the risk that it becomes chronic. In
addition, this article highlights important areas of focus for
clinical practice including: multimodal management of
CPSP patients, psychological modifiers of the pain experi-
ence, and the development of a Transitional Pain Service
specifically designed to manage patients at high risk of de-
veloping chronic post-surgical pain.
Key Points
The development of chronic post-surgical pain
(CPSP) is a complex process which involves
biologic, psychosocial, and environmental
mechanisms.
Ketamine (an NMDA antagonist) appears to be the
pharmacologic agent with the most consistent
positive preventive analgesic results.
The variation in patient response to pharmacologic
agents can be explained, in part, by genetic
polymorphisms.
Understanding the heritability of CPSP will be useful
when developing predictive algorithms to determine
the preoperative risk for developing CPSP.
Psychological treatments delivered before and after
surgery have the potential to influence the trajectory
of CPSP from the earliest days, in combination with
multimodal, preventive analgesia.
A novel multidisciplinary Transitional Pain Service
involving early detection and management of
patients at high risk for CPSP may modify the
postsurgical pain trajectory and reduce the incidence
of CPSP.
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1 Introduction
The development of chronic post-surgical pain (CPSP) is a
serious complication of major surgery. While most surgical
patients heal within months and return to their baseline
functional status, certain surgical procedures and surgical
candidates are at increased risk of developing CPSP and
using opioid medications in the long-term [1, 2]. Proce-
dures associated with a high incidence of post-surgical pain
include limb amputation (30–50 %), breast cancer surgery
(20–30 %), thoracotomy (30–60 %) and heart bypass sur-
gery (30–50 %) [3]. Currently, there is no universally
agreed upon definition of CPSP. However, Macrae and
Davies [1] define CPSP as pain that developed after a
surgical procedure, of at least 2 months duration, and not
the result of other causes or a pre-existing pain problem
[4].
While CPSP is not exclusively neuropathic in origin,
nerve injury and associated ectopic neural activity is im-
plicated as an important inciting factor in many cases [5].
In addition, inflammatory and immune reactions, following
axonal damage, result in the release of neurotransmitters
that act both locally and in the spinal cord to produce hy-
persensitivity. In turn, central sensitization characterized
by heightened dorsal horn neural activity and amplification
of sensory flow may alter central nervous system function
(CNS) and structure. Several proposed mechanisms for
CPSP include: sensitization of peripheral nociceptors/as-
sociated primary afferents and the potential growth of
aberrant neurons. These mechanisms lead to the clinical
presentation of allodynia (pain following an innocuous
stimulus) and hyperalgesia (an exaggerated response to
painful stimulus), which are suggestive of neuropathic pain
[3, 5]. Despite the evidence in support of intraoperative
nerve injury as a causal factor in the development of CPSP,
not all patients with CPSP have documented nerve injury
or neuropathic pain [6]. Moreover, many patients with
objective signs of nerve injury do not develop CPSP [7].
The development of CPSP is a complex process which
involves biologic, psychosocial, and environmental
mechanisms that have yet to be fully understood [8].
Preventive analgesia is distinguished from pre-emptive
analgesia in that the focus of treatment is less on the
relative timing of the analgesic or anesthetic intervention
and more on the mechanisms of action. Preventive anal-
gesia aims to decrease the impact of the nociceptive bar-
rage associated with noxious pre-operative, intra-operative,
and/or post-operative events/stimuli [9]. Currently periop-
erative pharmacologic interventions aim to suppress and
prevent sensitization with the goal of reducing pain and
analgesic requirements in acute as well as long-term pain.
For the purposes of this review, a preventive analgesic
effect is demonstrated when post-operative pain and/or
analgesic use are reduced beyond the clinical duration of
action of the target agent which we have defined as 5.5
half-lives of the target agent. This requirement ensures that
the observed effects are not analgesic effects [10].
The most common medication classes that have been
investigated as adjunctive medications to opioid-based
analgesia in the perioperative setting include: anticonvul-
sants, non-steroidal anti-inflammatories (NSAIDs), NMDA
receptor antagonists, local anesthetics, and antidepressants/
anxiolytics. A recent systematic review on the subject re-
lated to this concept was published by Chaparro et al. [11],
examining pharmacologic interventions for CPSP. As there
remains considerable uncertainty with respect to the phar-
macologic strategies best suited to reduce the development
of CPSP, and in fact whether this is even possible, this
review seeks to (1) update the Chaparro et al. review to
obtain the most recent published studies on the topic, (2)
discuss the efficacy of relevant drugs currently used for
CPSP, and (3) introduce novel clinical strategies aimed at
understanding the mechanisms underlying the development
of CPSP. Not only are pharmacologic interventions im-
portant to mitigate development of CPSP, psychological
management of patients with co-morbid psychological
vulnerabilities are needed in order to help improve the re-
covery trajectories of complex perioperative pain patients.
2 Literature Update
A systematic review of pharmacologic management of
CPSP was performed by Chaparro et al. [11]. In the present
narrative review, the Chaparro et al. search strategy was
implemented for the past year (January 2013–July 2014) in
order to provide an up-to-date comprehensive view of
current literature.
2.1 Primary Outcome
Studies reporting one or both of the following outcomes
were included for review in the present paper. Patient-re-
ported measures of pain 2 months or more following a
surgical procedure were included.
1. Proportion of participants reporting any pain at the
anatomical site of the procedure or pain around the
scar.
2. Severity of pain reported by participants at the
anatomical site 2 months or more after surgery.
2.2 Inclusion Criteria for Studies
Double-blind, randomized trials of one or more drugs ad-
ministered before, during, or after surgery; pain measured
using a validated pain assessment instrument 2 months or
more after surgery; participants of both genders; 18 years
of age or older; undergoing a planned surgical procedure.
2.3 Search Strategy
An update of the Chaparro et al. [11] review of pharma-
cotherapy for chronic post-surgical pain was conducted
from 2013 to 14 July 2014 using the same search strategy.
The literature search was conducted in MEDLINE,
EMBASE, and the Cochrane Central Register of Con-
trolled Trials on the OvidSP platform to identify random-
ized controlled trial results for chronic post-surgical pain
using main pharmacologic candidates to date. This in-
cluded anticonvulsants, ketamine, local anesthetics, an-
tidepressants, anxiolytic agents, and NSAIDs.
3 Search Results
The systematic search, conducted in August 2014 using the
Chaparro et al. search terms, identified 364 citations. The
results of the search were initially screened by two of the
review authors (MP & HC) based on the title of publication
and abstract contents. Screening of citation abstracts
yielded 15 records which were reviewed in full text. After
full-text review, nine studies fulfilled the inclusion criteria
and were included in the present review (Fig. 1). Five of
the nine studies examined local anesthetics in several sur-
gical populations [12–16], one study compared a tumor
necrosis factor-alpha (TNF-a) inhibitor (i.e., enteracept)
for inguinal hernia compared to placebo [17], another study
compared pregabalin versus placebo in a cardiac surgery
model [18], and another study examined minocycline (a
broad-spectrum cycline antibiotic which has been shown to
block microglial activation) compared to placebo following
lumbar discectomy [19]. These eight trials were negative
and did not demonstrate a preventive analgesic effect [12–
19]. Only one of the nine studies identified in our updated
literature search found a preventive effect on the incidence
of CPSP [20]. Patients who underwent total abdominal
hysterectomy and were induced and maintained solely with
propofol were found to have a significantly lower incidence
of CPSP (7/40 patients) compared to those who were in-
duced with propofol and then maintained with sevoflurane
(20/40 patients) for their general anesthetic [20]. Although
the mean pain scores were significantly lower in the
propofol group (0.78 ± 0.55) compared to the sevoflurane
group (2.23 ± 0.73, p = 0.01), scores for both groups
were in the mild range.
The results of the systematic review update are sum-
marized in Table 1.
4 Pharmacologic Management for the Prevention
of Chronic Post-Surgical Pain (CPSP)
4.1 Anticonvulsants
4.1.1 Gabapentin
The antinociceptive effects of gabapentin result, in part,
from its high affinity for the a2d subunit on pre-synaptic
voltage-gated calcium channels, which are often up-
regulated following nerve injury. This serves to inhibit
calcium influx and the release of excitatory neurotrans-
mitters, which elicits the sensation of pain [21]. One recent
meta-analysis supported the view that perioperative ad-
ministration of gabapentin was effective in reducing the
incidence of CPSP [22]. In contrast, in a more recent
systematic review by Chaparro et al. [11] on the use of
gabapentin for 3-month postoperative pain, none of the
included five studies demonstrated a significant difference
over placebo [11]. A total of 280 patients were analyzed, of
whom 71/133 patients receiving gabapentin and 79/147
patients receiving placebo went on to develop CPSP [11].
A similar non-significant result when comparing gaba-
pentin and placebo was found for 6-month postoperative
pain. However, at the 6-month time-point, it is important to
The three databases were 
screened without removing 
duplicates
364 records were 
screened
350 records 
were excluded
15 full-text 
articles were 
assessed for 
eligibility
9 studies were 
included in 
analysis
6 full-text articles 
were excluded
1 population out 
of the scope of 
the review
5 followed up less 
than 2 months
Fig. 1 Chaparro update 2013–2014 study flow diagram
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recognize that only two studies were included in the ana-
lysis [23, 24]. In two studies that were excluded from Sen
et al. [25, 26], postoperative pain scores were significantly
lower in the gabapentin group compared with both the
ketamine and control groups at 3- and 6-month follow-up
following hysterectomy and inguinal herniorrhaphy, re-
spectively. In the remaining excluded gabapentin trial, no
significant difference was found between gabapentin and
placebo for pain characteristics at 6 months [27]. Although
the conclusion from Chaparro et al. was that that gaba-
pentin does not reduce the incidence of CPSP, the small
sample size of the studies limits these interpretations,
especially when considering that these results derive from
heterogeneous surgical procedures. Brogly et al. [28] found
that 1200 mg of gabapentin administered before surgery
reduced chronic but not early acute postoperative pain
following superficial cervical plexus block [28]. The lack
of standardized gabapentin doses between studies may
have contributed to inconsistencies in the drug’s efficacy at
reducing the incidence and severity of CPSP. It has been
well documented that the absorption profile of gabapentin
in humans is inconsistent due to the active and saturable a-
amino acid transport system [29]. Thus, the bioavailability
of any given dose varies from 35–90 % [29]. Without
plasma samples, one cannot confirm therapeutic drug
concentrations of gabapentin, as such it is possible that the
higher doses of gabapentin may enable therapeutic plasma
levels needed to demonstrate preventive effects with re-
spect to the reduction of CPSP. Another possibility for the
lack of an effect on CPSP is the heterogeneity of the sur-
gical populations studied to date, perhaps if focused on
procedures that are associated with significant neuropathic
pain (i.e., spine, joint, thoracotomy, and amputations) the
preventive benefits of gabapentinoid perioperative admin-
istration may become evident. However, in a recent study
outside of the 1-year literature update, gabapentin failed to
reduce the incidence or intensity of CPSP when compared
to placebo 3 months after total knee arthoplasty [30]. Re-
cently, the available literature indicated that perioperative
gabapentin was effective in preventing CPSP [22]; how-
ever, Chaparro et al. [11] suggest equivalence to placebo in
their review.
4.1.2 Pregabalin
Pregabalin is a structural analog of c-aminobutyric acid.
Similar to gabapentin, pregabalin inhibits Ca2? currents by
binding the a2d1 subunit on pre-synaptic voltage-gated
calcium channels [31]. In Chaparro et al.’s [11] systematic
review, five pregabalin trials with long-term pain outcomes
were previously identified, of which two studies demon-
strated a significant benefit of pregabalin as compared to
placebo [32, 33]. While the results between the studies were
quite heterogeneous at 3-month follow-up, an overall sig-
nificant effect of pregabalin was found [11]. Forty-eight of
217 patients developed CPSP in the pregabalin group
compared to 70 of 222 patients in the placebo group. The
literature update identified one study that did not find a
significant difference between patients that received
150 mg of pregabalin 2 h prior to induction of anesthesia
and 75 mg twice daily for two postoperative days compared
to placebo in 40 patients undergoing coronary artery bypass
surgery 3 months following surgery [18]. Buvanendran
et al. [33] did find a significant reduction in the incidence of
CPSP 6 months following total knee arthroplasty in patients
who were randomized to receive a 300-mg preoperative
dose of pregabalin followed by a 14-day twice-a-day (BID)
regimen of pregabalin (50–150 mg) or placebo [33]. The
heterogeneity of dosing regimens studied to date is prob-
lematic with respect to comparing long-term outcomes.
Overall, despite the heterogeneity between studies, avail-
able literature favors the perioperative use of pregabalin to
prevent CPSP; however, when unpublished data are taken
into consideration [34] and in light of a new publication
which is outside of this review [35], this conclusion needs to
be reassessed.
4.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
The analgesic effects of NSAIDs have been attributed to
their anti-inflammatory properties with respect to inhibiting
the synthesis of prostaglandins [36]. The identification of
two COX isoforms, COX-1 and COX-2, which catalyze the
first two reactions in the prostaglandin pathway enabled
efforts to characterize the relative contribution of each
isoform to inflammation and pain [37]. The COX-2 isoform
appears to be the enzyme responsible for inflammation and
pain. COX-2 inhibitors, such asparecoxib, reduce sec-
ondary hyperalgesia and appear to reduce central sensiti-
zation in humans [38, 39]. Celecoxib (the only COX-2
inhibitor approved in the North American marketplace) has
demonstrated a reduction in postoperative pain, a reduced
need for postoperative opioid analgesia [40], and did not
inhibit bone healing following arthroplasty surgery [41].
There is no meta-analysis of NSAIDs for CPSP currently in
the literature. Clinical trials are heterogeneous and differ in
type of drug used, follow-up time-point, and pain out-
comes. Three prospective, randomized perioperative trials
have reported results of NSAIDs for CPSP [42–44], none
of which have demonstrated a significant impact of
NSAIDs (in isolation) with respect to a reduction in inci-
dence or severity of CPSP [42–44]. No additional trials
were identified in the 1-year literature update performed in
this review.
4.3 N-Methyl-D-Aspartate (NMDA) Receptor
Antagonists
4.3.1 Ketamine
The NMDA receptor plays a critical role in both the in-
duction and maintenance of central sensitization and
pathologic pain [45]. Ketamine (a non-competitive NMDA
receptor antagonist) is believed to reduce pain and anal-
gesic consumption through the prevention of NMDA-me-
diated sensitization of spinal cord dorsal horn neurons [46].
Fourteen trials comparing ketamine to placebo for CPSP
have been previously identified [11], of which 12 were
used in the Chaparro et al. [11] systematic review [47–
54].The majority of trials identified used pre-incisional
loading doses of ketamine ranging from 0.15 to 1 mg/kg,
plus an intraoperative infusion. A total cumulative dose of
less than 1 mg/kg was reached in 6/14 studies, 4/14 studies
administered a cumulative dose of ketamine between 1 and
2 mg/kg, and 4/14 administered a dose greater than 2 mg/
kg [11]. While ketamine showed a non-significant effect
for the reduction of CPSP 3 months after surgery, a sub-
group analysis of trials with patients receiving longer than
24 h of ketamine treatment demonstrated ketamine’s su-
periority over placebo [11]. A more definitive result was
found for ketamine 6 months following surgery, with an
overall significant decrease in the incidence of CPSP. Six
months following surgery, studies in which patients re-
ceived ketamine for less than 24 h demonstrated a reduc-
tion in the incidence of CPSP compared to studies in which
patients received ketamine for more than 24 h. A total of
55 of 285 patients on ketamine developed CPSP at
6 months, compared to 79 of 231 patients who received a
placebo [11]. Two trials that examined the effects of ke-
tamine administration were excluded from the Chaparro
et al. systematic review as they did not report the outcomes
of interest. In the first study, postoperative pain scores were
significantly lower in patients treated with gabapentin as
compared to patients who received ketamine or placebo. In
this trial, a 0.3 mg/kg intravenous (IV) bolus and 0.05 mg/
kg per hour infusion of ketamine was not found to be
significantly different to placebo [25]. In a study of 120
patients, Dullenkopf [55] did not find a difference in pain
scores at 3 months between patients treated with placebo
and either 0.15 mg/kg ketamine IV or 0.5 mg/kg ketamine
IV given pre-incision. While the use of ketamine to reduce
CPSP is empirically promising, the results still remain
controversial due to the wide variability in clinical settings,
ketamine regimens, and reported outcomes. In addition,
some of the positive results have been obtained using
clinical anesthesia regimens which are not accepted as
standard treatments [55, 56]. Since Chaparro et al.’s sys-
tematic review no ketamine trials were identified which
examined CPSP outcomes. Overall, the available literature
supports the perioperative use of ketamine to prevent
CPSP.
4.3.2 Other NMDA Receptor Antagonists
Other NMDA receptor antagonists have not been studied as
extensively as ketamine. In one study of 19 patients, me-
mantine was found to significantly reduce the incidence
and intensity of phantom limb pain in patients undergoing
traumatic amputations when used in combination with a
regional block [57]. Another study on the effects of
amantadine for CPSP found that all patients treated with
amantadine developed CPSP (9/9) compared to 75 % of
patients who received a placebo (6/8) [58]. Further study of
these agents may be warranted. No studies were identified
with our literature update in the past year which examined
memantine or amantadine for the reduction of CPSP. The
current body of literature available is insufficient to de-
termine efficacy.
4.4 Local Anesthetics
Local anesthesia is an important adjunct used to decrease
pain, opioid consumption, and opioid-related adverse ef-
fects [59]. For CPSP, local anesthetics may have clinical
utility through early interruption of sensory information to
the dorsal horn of the spinal cord [60]. The analgesic action
from local anesthetics is based on the suppression of ab-
normal sodium channels that exist along injured neurons
via cellular mechanisms such as the inhibition of G protein-
coupled receptors and NMDA receptors [61, 62]. Inde-
pendent studies have sought to determine the effect of
several different local anesthetics on CPSP. Patients who
received intravenous lidocaine during breast cancer surgery
had a lower incidence of CPSP 3 months following surgery
[63]. Patients randomized to IV lidocaine were found to
have significantly lower pain scores, with fewer patients
developing CPSP (2/17 patients) or secondary hyperalgesia
compared to patients randomized into the placebo group (9/
19) at 3 months. Fassoulaki et al. [60] evaluated the use of
mexiletine in a pair of clinical trials. In a randomized,
placebo-controlled trial, the incidence of CPSP and pain
scores did not differ between study arms. Similarly, in their
second trial comparing mexiletine to gabapentin and
placebo, no significant difference was found between trial
groups [64]. Within the past year, an additional five studies
have been published evaluating the use of local anesthetics
for CPSP [12–16]. No significant difference in incidence or
pain score was found for any of the agents 2 months or
more following the surgery. While there is some evidence
in support of the use of local anesthetics, the agents used
are heterogeneous and the sample sizes quite small. Further
investigation is needed in order to draw more meaningful
conclusions. To that end, different routes of delivery for
local anesthestics (beyond PO, neuraxial, and IV), such as
medial open transversus abdominis plane (MOTAP)
catheters which deliver local anesthetic into the abdominal
cavity to anesthetize the neural plexus supplying the an-
terior abdominal wall cephalad to the umbilicus (der-
matomes T6–10), are currently being investigated in the
perioperative setting following liver resection and other
major surgical interventions to study secondary effects
such as the development of CPSP [65]. To date, the
available literature suggests that local anesthetics as a class
are equivocal to placebo for CPSP. However, there is
limited evidence that favors the use IV lidocaine for CPSP.
4.5 Selective Norepinephrine and Serotonin Re-Uptake
Inhibitors (SNRIs)
Venlafaxine hydrochloride is an antidepressant medication
that inhibits the neuronal reuptake of serotonin and nore-
pinephrine. However, it has a better safety profile as it does
not bind to cholinergic, histamine, or a1-adrenergic binding
sites [66]. In a study comparing venlafaxine to gabapentin
and placebo, venlafaxine was found to significantly reduce
the incidence of CPSP at 6 months in women having breast
surgery [27]. The literature regarding SNRI use for the
prevention of chronic post-surgical pain is limited; how-
ever, given that the SNRI medication (duloxetine) is a first-
line medication for the treatment of chronic neuropathic
pain [67], its role in the prevention of chronic post-surgical
pain should be further investigated. Duloxetine has been
shown to be efficacious for the treatment of diabetic pe-
ripheral neuropathy and fibromyalgia [68–71]. Appropri-
ately powered trials are necessary to examine the efficacy
of the SNRIs in CPSP prevention, including dose-response
studies and head-to-head comparisons with other drugs,
such as pregabalin. In the past year, no new studies ex-
amined the role of the SNRIs for the reduction of CPSP.
The current literature regarding SNRIs is insufficient to
determine efficacy with respect to the prevention of CPSP
and further studies are needed.
4.6 Multimodal Analgesia
The concept of multimodal analgesia for treating periop-
erative pain has become widely accepted and standard
multimodal analgesic regimens tailored to specific surgical
procedures have been adopted by many institutions [18].
Utilizing different classes of medication to target different
peripheral and CNS mechanisms to reduce acute pain, re-
ducing opioid analgesic requirements postoperatively and
improving opioid related side effects has been shown to be
successful in clinical trials [60, 64]. However, RCTs that
examine specific surgery-related multimodal regimens
versus placebo and follow patients for preventive analgesic
effects (i.e., 3 months or greater following surgery) are
limited. We identified two trials comparing multimodal
analgesic regimens to placebo in the published literature,
both of which demonstrated positive preventive effects at
3 months [72] and the other at 1 year [73] following sur-
gery. Multimodal pain regimens that include gabapentin,
NSAIDs, acetaminophen, and regional anesthesia were
effective in controlling perioperative pain and decreasing
perioperative opioid use following arthroplasty surgery
[74, 75]. The literature has highlighted the need for studies
focused on multimodal analgesic protocols for colorectal
[76], thoracic, amputation, mastectomy [77], orthopaedic
[37], and liver resection surgeries [65]. In these trials, the
outcome of interest should not only focus on reducing
acute postoperative pain and opioid consumption (due to
the immediate drug effect), but also on ascertaining whe-
ther preventive effects that reduce the incidence and
severity of CPSP are demonstrated.
5 Genetics of CPSP
There is a large variability with respect to the development
of CPSP amongst patients undergoing the same surgery.
This individual variability suggests that there are several
factors which contribute to the development of CPSP (both
genetic and environmental). Recent reviews in pain ge-
netics estimate that chronic pain heritability ranges from 30
to 70 % [78]. Presently it is not possible to ascertain the
extent to which individual genetic factors contribute to a
person’s propensity to develop chronic postsurgical pain or
their response to therapy [79].
A number of candidate genes have been identified for
chronic pain, including a few for post-surgical and post-
traumatic pain. These include genes encoding for ion
channels, neurotransmitter enzymes, receptors, trans-
porters, transcription factors, and hormone receptors that
increase the risk for pain chronicity [79]. While there are
numerous studies that are ongoing, variations of three ge-
nes mapped in rodent models have been associated with
chronic pain in humans. These candidate pain genes are
KCNSI (encoding the s1 subunit of a voltage-dependent
potassium channel), CACNG2 (encoding the gamma sub-
unit 2 of a voltage-gated calcium channel), and the P2RX7
gene (encoding the P2X7 purinergic receptor, an
ionotrophic adenosine-triphosphate-gated receptor that
operates purinergic synapses in the CNS) [80–82]. In ad-
dition to polymorphisms that affect the development of
chronic pain, polymorphisms can affect a patients’ re-
sponse to pharmacologic agents. Specificpolymorphisms
that influence the metabolism of medications have been
identified. The identified polymorphisms affect the cy-
tochrome P450 enzymatic pathway [83]. Therapeutic re-
sponse to medications can be guided with known genetic
information and patients can be classified as a normal,
intermediate, poor, rapid, or ultrarapid metabolizer. For
opioid metabolism, the relationship of pain and polymor-
phisms of cytochrome P450 enzymes (CYP2D6, CYP2B6,
and CYP3A4) are well documented [83]. In a study by
Yang et al. [84], 71 % of postoperative patients with acute
severe pain had the CYP2D6 poor metabolizer genotype. In
a separate analysis, ultrametabolizers for CYP2D6 also
demonstrated higher efficiency in synthesizing endogenous
morphine compared to other CYP metabolizer groups and
required significantly less morphine in the postoperative
period [85].
Presently, it is not possible to predict which individuals
may be susceptible to the development of CPSP. However,
it is important to recognize that gene polymorphisms that
exist in a patient population may end up determining dif-
ferent responses to treatment. The ultimate goal of pain
genetics is to enable clinicians to predict preoperatively
who is at risk of developing CPSP and translate this un-
derstanding into pharmacologic and surgical decision-
making. Improved knowledge could contribute to person-
alized preventive pain treatments and allow management to
move away from the current symptom-based approach
[79].
6 Development of a Transitional Pain Service
The call for the implementation of clinical programs and
research into risk factors associated with the transition of
acute to chronic post-surgical pain has been longstanding
[86–88]. However, equally problematic but less often dis-
cussed is the issue of prolonged opioid use associated with
CPSP. Given that one in 33 previously opioid-naı¨ve pa-
tients who undergo major surgery continue to refill their
opioid prescription up to 6 months following surgery [2],
the time has come to focus on the antecedent predictors of
persistent opioid use and the development of post-surgical
pain. Furthermore, there is a vulnerable population of
complex pain patients (often excluded from randomized
controlled trials) who present with pre-existing pain syn-
dromes and who use significant amounts of opioid anal-
gesics pre- and perioperatively. These patients are often
managed quite poorly and may leave the hospital on more
analgesic medications than when they were triaged pre-
surgically [89, 90]. It is important to prospectively deter-
mine which patients should be aggressively treated within
the perioperative time period in the hopes of reducing the
alarming percentage of patients (25 %) referred to tertiary
pain care centers presenting with a CPSP condition [4].
We have developed a Transitional Pain Service (TPS) to
target patients at high risk for the development of acute and
chronic post-surgical pain, as well as the development of
persistent opioid use following surgery. These include but
are not limited to patients with (1) a current/previous his-
tory of chronic pain; (2) previous/current drug misuse or
abuse; (3) patients with previous/current psychological co-
morbidities; (4) current/previous opioid therapy for pain;
(5) patients on methadone or buprenorphine; (6) patients
followed by our Acute Pain Service for an extended period
of time for poorly managed pain; (7) patients consuming
excessive amounts of postoperative opioids
(e.g., [90 mg/day); and (8) any patient referred to the TPS
by an attending surgeon at our facility. Once a patient has
been identified as requiring the services of the TPS, a nurse
practitioner commences a program of enhanced teaching
with the patient while in hospital. Communication with
primary care is initiated while in hospital. Once a patient
has been deemed medically fit for discharge, patients are
sent home with a TPS clinic visit scheduled within days of
discharge to see one of the TPS attending physicians (while
receiving follow-up calls from the TPS team coordinator
until the scheduled appointment).
At the initial visit to the outpatient TPS clinic after
surgery, a detailed pain treatment plan including an opioid-
weaning strategy is discussed with each patient (and family
members if present). Patients are assessed for opioid ad-
diction risk and an opioid agreement contract is signed if
necessary. Patients are assessed once every 2 weeks and
their opioid medications and other analgesics are adjusted
until they are at a safe level, their pain is under control, and
their daily function approaches their pre-surgical level (or
better). The aim is to transition patients back to their pri-
mary-care physicians within 6 weeks to 3 months of hos-
pital discharge (i.e., after 3–6 visits).
For these patients, we are currently combining periop-
erative psychological treatments (e.g., Acceptance and
Commitment Therapy), as well as holistic alternative
medicine treatments (e.g., acupuncture), and traditional
pharmacologic management. In preliminary analyses, pa-
tients report decreased pain intensity over time while being
treated by TPS. Pain trajectory data from the first 4 months
of our service show lower numeric pain rating (NRS)
scores (NRS pain at discharge 5.1 ± 2.7, and at 2 months
2.7 ± 2.9) when compared to a non-TPS thoracic surgery
cohort of patients (NRS pain at discharge 7.7 ± 1.6, at
3 months 4.8 ± 1.5) followed prospectively in a TGH Pain
Research Unit study (Fig. 2). The data also indicates better
hospital pain management (p \ 0.05) and a faster trajec-
tory to mild pain (NRS \4) with TPS involvement.
Cousins et al. [91] have identified the economic burden
of acute postoperative pain that progresses to a chronic
pain syndrome in a 30-year-old individual is as much as
US$1 million over the course of their lifetime [91]. The
TPS has been developed and designed to identify complex
perioperative pain patients at risk for the development of
CPSP, institute early interventional practices, reduce the
wait time for referral back to chronic pain specialists, and
save the health-care system significant direct and indirect
costs.
6.1 Psychological Predictors and Means of Intervening
Elsewhere we have argued that the true power of preven-
tive, multimodal treatment to impact the trajectory of post-
surgical pain can only be realized by the integration of
psychological interventions into the patients’ pre- and post-
surgical care [8]. Pain after surgery—in the aftermath of
incision, intra-operative tissue damage and the ensuing
inflammatory cascade—is subject to a host of psychosocial
influences, including those related to mood and attention
[92]. Psychosocial risk factors of particular concern with
respect to CPSP include pre-surgical depression, anxiety,
surgical fear [93], and emotional numbing [94]. Pain
catastrophizing (rumination, magnification, and helpless-
ness) after surgery may confer added risk of CPSP,
although findings have been mixed and may be surgery-
specific [8]. Innovative research from our group has iden-
tified subgroups of patients with distinct post-surgical pain
trajectories. Both pre-operative pain and anxiety are risk
factors for continued pain at 12 months after TKA [95] and
we have provided evidence that pain catastrophizing pre-
dicts chronic post-surgical pain following TKA in a recent
systematic review [96]. Over the long term, persistent pain
increases vulnerability to distress, which potentiates pain
perception, and can lead to a vicious cycle in which pain
and distress amplify one another [94].
Psychological treatment (most frequently cognitive-be-
havioral therapy) is a well established and empirically
supported component of multidisciplinary pain programs
that has been shown to interrupt this kind of vicious cycle
and lead to improved patient outcomes [97]. Patients who
have participated in psychological interventions for chronic
pain (including Cognitive Behavioral Therapy [98] and
Acceptance and Commitment Therapy [99, 100]) report
less pain, pain-related disability, and mood disturbance.
Despite the effectiveness of these programs in terms of the
patient’s quality of life, chronic pain patients often have
difficulty accessing them until pain is well established and
all other medical options have been exhausted. In contrast,
for most surgeries, the nature of the injury and time of
onset of pain are known in advance and patients are ac-
cessible through the hospital system [8]. Surgery therefore
offers a unique opportunity to reach patients early—even
before surgery—to influence psychological variables such
as pre-surgical anxiety. Early evidence indicates this ap-
proach is promising in terms of outcomes in the acute post-
surgical time period [101, 102]; the impact of psycho-
logical intervention on the prevention of persistent pain is
yet to be demonstrated. Psychological treatments delivered
at the pre-surgical and acute post-surgical time points have
the potential to influence the trajectory of CPSP from the
earliest days, in combination with multimodal, preventive
analgesia. There is a growing call for such interventions
and they are in the early stages of being developed and
empirically tested [93, 103].
7 Future Directions
The heterogeneity with respect to the timing of interven-
tions, the time points studied, and the outcomes assessed
limit meaningful comparison of CPSP trials to date .There
were two negative trails identified in this review which
focused on minocycline [19] and entanercept [17] as pos-
sible agents that may play a role in modifying the transition
from an acute pain to chronic pain. The role of tumor
necrosis factor-alpha (TNF-a) inhibitors and medications
implicated in the blocking of microglial activation deserve
further study. Future trials should focus on the acute and
subacute postoperative period and early pharmacologic and
non-pharmacologic interventions that may modify the pain
trajectory and reduce the incidence of CPSP. Standard-
ization of methodology and reporting of CPSP studies is
required to elucidate future optimal management of pa-
tients experiencing CPSP. It is also important to recognize
that not all pain can be eliminated. Consequently, goal-
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Fig. 2 Comparison of numerical pain rating scale (NRS) scores for
patients followed by a Transitional Pain Service (TPS) compared to a
thoracic surgery cohort control group
related therapies aimed at an improvement in quality of life
and function are potentially more appropriate outcomes
than a reduction in numeric pain rating scales 3 or
6 months following major surgery.
8 Conclusions
In the past year, the updated literature search identified
only one randomized trial which demonstrated a significant
reduction in CPSP. The focus on treatment strategies aimed
at the reduction of CPSP continues to be a field in which
much more research is needed. The heterogeneity of dosing
regimens complicates the ability to draw meaningful con-
clusions with respect to the preventive effects of each
pharmacologic agent. Future studies should focus on pro-
cedures that elicit pronociceptive (acute hyperalgesia)
mechanisms (e.g., joint arthroplasty, thoracotomy) because
studying surgeries that have a higher incidence/severity of
CPSP would increase the likelihood of revealing preven-
tive effects. Using the IASP recommendations for the
assessment of core measures and domains in clinical trials
which includes relevant psychological, emotional, and
physical variables in addition to those routinely assessed
(i.e., pain and analgesic use), may highlight predictors
which increase the risk for developing chronic post-surgi-
cal pain [104]. Moving forward, effects of multimodal
analgesic regimens should be studied beyond 2 months
following surgery in order to determine whether multi-
modal pharmacotherapy is effective in reducing the de-
velopment of CPSP. The implementation of a Transitional
Pain Service will enable early referral for interventional
pain procedures, psychoeducation, and targeted mental
health interventions for patients identified as at high risk
for CPSP. These services tailored specifically to the indi-
vidual surgical patient are aimed at improved in-hospital
acute pain control, lower post-discharge pain scores, ef-
fective weaning of opioid medications, improved quality of
life, and reduced pain disability, as well as a significantly
lower risk of CPSP.
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